One of the most troubling realities of multiple sclerosis (MS) is that even when therapies are controlling acute flare-ups and scans show no new lesions, patients may not feel better. A person living with MS may still experience fatigue, brain fog or muscle weakness—”invisible” symptoms that slowly amass over time.

1 in 4

Increasingly, physicians are recognising this often overlooked problem. In one study, one in four people with MS showed hidden progression,¹ a slow but steady worsening of symptoms thought to be driven in part by "smouldering neuroinflammation" within the central nervous system.

“Patients come to me asking: ‘Why am I feeling worse though I’m not having relapses and my scans look stable? I feel that my walking is not as good as the year before.  I used to be able to go out for a half-mile walk and now every 500 metres I need to stop,’” says Antonio Scalfari, a neurologist at Imperial College Healthcare National Health Service Trust. “Emerging evidence indicates that their deterioration stems from underlying smouldering pathological processes that current therapies fail to address.”

The need to act

Experts such as Dr Scalfari say the next advances in MS treatment and symptom management will depend on better understanding how smouldering neuroinflammation clinically manifests in order to enable physicians to detect such subtle symptoms and to address this hidden gap in clinical care. This will pave the way for developing new treatments able to target the smouldering neuroinflammation.

Dr Scalfari recently led a landmark 2024 consensus paper published in Annals of Neurology, co-authored by 15 MS international experts and commissioned by Sanofi, which made the case for dedicating greater research attention to smouldering neuroinflammation and its clinical manifestations.

Doctor examining MRI images of patient with multiple sclerosis at table in clinicA male physiotherapist assisting a senior patient in recovery

“We felt it was needed to make a big statement for the research community to highlight these symptoms,” he says. Among the recommendations: routinely study smouldering neuroinflammation in clinical practice and clinical trials, and investigate its clinical and radiological biomarkers that can be used to monitor the potential effect of therapies.

The power of listening

Researchers continue to work towards untangling the mechanisms that drive smouldering neuroinflammation in the central nervous system by exploring individual cells, genes and proteins. Part of the challenge, explains Luis Felipe Orozco, Sanofi’s global medical head of neurology, is understanding why smouldering neuroinflammation shows up differently in different people and how the mechanisms interrelate.

“In some people, it’s fatigue, but in others it might be bowel or sexual dysfunction, and in others it might be cognitive dysfunction,” he says.

To shed light on the spectrum of symptoms and its early detection—what Dr Orozco calls “disability accumulation”—Sanofi is also supporting the smouldering-associated worsening (SAW) Index Study.  The purpose of this study is not only to improve understanding of SAW and its impact on people living with MS, but also to help support the identification and measurement of SAW in clinical care. 

The research team has interviewed people living with MS in six countries about their experiences via qualitative interviews. This has helped to identify 15 domains beyond physical symptoms, including lesser-known ones such as changes in taste and difficulty swallowing. This research aims to inform an evidence-based framework to identify, assess and measure SAW in people living with MS.

In the meantime, doctors can emphasise listening to their patients describe how their symptoms change over time so they can better monitor and adjust care recommendations. This starts by asking them, on a regular basis, how they are feeling.

“Perhaps a simple pen-and-paper questionnaire can help determine if there’s some sort of disability progression in patients, even if doctors don't have access to the technology to measure blood biomarkers,” Dr Orozco suggests.

Putting symptoms on everyone’s radars

Spotting subtle MS symptoms can be difficult, especially when they emerge slowly over months or years. Digital technology can help, says Dr Orozco. Wearable technology, sensors and apps that encourage people living with MS to document how they are feeling and share that information with their doctors.

Sanofi is pursuing several partnerships to develop tools to capture this gradual deterioration. The MS-DETECT study is studying how 336 people living with MS in seven countries use a smartphone app called MSCopilot® Detect. The app tracks how long it takes them to walk one kilometre, how far they can walk in six minutes and how well they can trace six shapes with their finger.

“Through digital biomarkers, we have a lot of opportunity to capture the small variances that happen in people living with the disease, thus increasing our capacity to detect disability accumulation and do something about it,” Dr Orozco explains.

Amanda Montague, interim president and CEO at the Multiple Sclerosis Association of America, underscores the urgency. “Catching these shifts as early as possible will be key to identifying people who might benefit from new treatments that could delay their progression,” she says.

Her organisation provides a phone app called My MS Manager. The app features measurement scales including fatigue, depression and bladder control. Such tracking tools, she adds, are important in empowering people with MS to be more in tune with their bodies.

Doctor looking at brain scan

“We’re seeing a new age of biomarkers that might actually play a big role here in helping patients and doctors make medical decisions that are based on real data,” she says.

Such data will help to make smouldering neuroinflammation less of a mystery for physicians, patients and care partners, and more of a routine topic of conversation in managing and treating MS, adds Ms Montague. “It's an extraordinarily hopeful time in MS,” she says. “We've come so far in such a short time, and our understanding of MS continues to evolve in a way that I think is going to really help people living with this disease manage it in a different way.”

References
  • 1.
    JAMA Neurology, Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis, 2022.